ALT - NASDAQ

Altimmune, Inc.

ALT·NASDAQ

$2.87

-1.0%

HealthcareBiotechnology

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$253.30M

EPS-1.0000

P/E Ratio-2.87

Earnings Date08/06/2026

279.93M

Assets

101%

3Y+35.0%

5Y+14.0%

10Y+25.0%

55.04M

Total Liabilities

248%

3Y+154.0%

5Y+186.0%

10Y-73.0%

224.89M

Total Equity

82%

3Y+21.0%

5Y-

10Y+1056.0%

Altimmune, Inc. Funding & Solvency Profile

ALT · NASDAQ

Current Assets

Cash & Cash Equivalents43.76M

Net Receivables1.74M

Inventory0.00

Other Current Assets3.00M

Total Current Assets278 M

Non-Current Assets

Property, Plant & Equipment312.00K

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets1.43M

Total Non-Current Assets2 M

Total Assets

279.93M

Financial Health Analysis

Current Ratio

18.55x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.24x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

263 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

99% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Altimmune, Inc. Balance Sheet

ALT • NASDAQ

Altimmune, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	43.8M	36.9M	135.1M	111.1M	190.3M	115.9M	9M	33.7M	8.8M	154M	15.6M	18.6M	10.5M	12.7M	11.2M	11.8M	2.7M	19.8M	40.6M	675.3K
Short-Term Investments	229.7M	95M	62.7M	73.8M	0.0	100M	28.3M	0.0	0.0	66.8M	0.0	0.0	0.0	0.0	0.0	0.0	3.1M	3.2M	12.2M	0.0
Cash & Short-Term Investments	273.5M	131.9M	197.8M	184.9M	190.3M	215.9M	37.2M	33.7M	8.8M	220.8M	15.6M	18.6M	10.5M	12.7M	11.2M	11.8M	5.8M	22.9M	52.7M	675.3K
Net Receivables	1.7M	3.1M	4.9M	2.5M	5.8M	12.4M	1.7M	4.5M	10.2M	999.1K	1.5M	408.1K	3.6M	6.5M	7.9M	9.7M	18.7M	10.3M	5.2M	1.5M
Accounts Receivables	1.2M	544K	1.1M	173K	429K	4.6M	1M	3.5M	3.8M	383K	512K	110.7K	1.4M	2.4M	7.9M	5.4M	8.9M	3.8M	5.2M	1.5M
Other Receivables	518K	2.6M	3.7M	2.4M	5.4M	7.8M	629.1K	1M	6.4M	807.5K	963.3K	297.4K	2.2M	4.1M	0.0	4.3M	8.6M	6.5M	0.0	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	-503.9M	0.0	3.5M	0.0	0.0	0.0	0.0	0.0	0.0	1.1M	0.0	0.0	476.5K	0.0
Prepaids	0.0	0.0	0.0	0.0	8M	1.9M	470.2K	548.1K	994.3K	420.4K	181.7K	11.9K	231.5K	547.2K	830.6K	1M	973.2K	917.1K	476.5K	877.6K
Other Current Assets	3M	2.2M	7M	5.4M	33.3K	34.2K	503.9M	634.4K	3.5M	807.5K	0.0	0.0	0.0	0.0	100K	1M	0.0	12M	15.8K	104.8K
Total Current Assets	278.2M	137.3M	209.6M	192.8M	204.1M	230.3M	39.4M	39.4M	23.5M	222.3M	17.2M	19.3M	14.3M	19.8M	19.6M	23.6M	24.2M	46.1M	58.5M	71.7M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	312K	413K	651K	1.1M	1.4M	2M	1.8M	1.3M	603.1K	120.9K	233.7K	325.8K	386.1K	484K	788.7K	1.2M	6.3M	5.3M	6.6M	0.0
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.8M	22.5M	2.3M	2.3M	2.3M	2.3M	2.3M	2.3M	2.5M	0.0	0.0
Intangible Assets	0.0	0.0	0.0	12.4M	12.4M	12.8M	12.7M	13.9M	38.7M	15M	17.8M	0.0	0.0	0.0	0.0	0.0	928.6K	925.5K	1.3M	0.0
Goodwill & Intangible Assets	0.0	0.0	0.0	12.4M	12.4M	12.8M	12.7M	13.9M	38.7M	33.7M	40.3M	2.3M	2.3M	2.3M	2.3M	2.3M	3.3M	3.4M	1.3M	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-58.5M	-5.9B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	58.5M	5.9B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	1.4M	1.6M	363K	615K	872K	73.4K	128.5K	183.7K	238.9K	0.0	53.4K	53.4K	65.7K	113.1K	53.4K	88.4K	309K	1.5M	252.5K	0.0
Total Non-Current Assets	1.7M	2.1M	1M	14.1M	14.7M	14.9M	14.7M	15.4M	39.6M	2.5M	2.6M	2.7M	2.8M	2.9M	3.2M	3.6M	9.8M	10.2M	8.1M	0.0
Total Assets	279.9M	139.3M	210.6M	206.9M	218.9M	245.1M	54.1M	54.8M	63M	224.7M	19.9M	22M	17.1M	22.7M	22.8M	27.2M	34.1M	56.4M	66.6M	71.7M
LIABILITIES
CURRENT LIABILITIES
Total Payables	2.7M	211K	2.1M	6M	2M	612.3K	18.2K	372.9K	129.1K	2M	521.1K	391.4K	1.1M	1.7M	1.4M	3.1M	1.9M	3.9M	1.4M	839.1K
Accounts Payable	2.7M	211K	2.1M	4.8M	2M	612.3K	18.2K	372.9K	129.1K	2M	521.1K	391.4K	1.1M	1.7M	1.4M	3.1M	1.9M	3.9M	1.4M	839.1K
Other Payables	0.0	0.0	0.0	1.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	12M	10M	9.6M	10.6M	9.7M	2.4M	1.2M	1.3M	1.7M	2.4M	703K	37.3K	966.2K	189.7K	752.5K	778.7K	1.3M	936.3K	856.7K	58.9K
Short Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	71.6K	49.7K	458.6K	0.0	746.1K	2.1M	2.1M	0.0	0.0	0.0	17.4M	4M	0.0
Capital Lease Obligations (Current)	256K	279K	496K	452K	411K	356.7K	259.4K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	1.2M	0.0	0.0	0.0	0.0	0.0	3.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	19.8K	61.6K	19.8K	19.8K	19.8K	-537.7K	1.2M	341.7K	1.4M	0.0	0.0	0.0	0.0	3M	591.6K
Other Current Liabilities	0.0	0.0	0.0	0.0	6.1M	8.7M	2.4M	2.8M	1.9M	620.6K	955.3K	1.4M	2.3M	2.1M	2.4M	2.3M	10.2M	13.7M	2.7M	13.3M
Total Current Liabilities	15M	10.5M	12.1M	17.1M	18.3M	12M	3.9M	4.5M	3.8M	204.8M	2.2M	2.6M	6.8M	7.5M	4.6M	6.2M	13.5M	35.9M	9M	1M
NON-CURRENT LIABILITIES
Long Term Debt	34.3M	0.0	0.0	0.0	0.0	0.0	0.0	501.2K	599.9K	526K	0.0	0.0	730.3K	1.7M	0.0	0.0	17.4M	928.1K	16.7M	0.0
Deferred Revenue (Non-Current)	160K	0.0	0.0	0.0	0.0	250K	250K	1.1M	159.7K	179.4K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	-250K	-240K	58.5K	5.9M	-705.4K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	4.4M	3.9M	4.2M	3.9M	330K	5.8M	3.1M	1.4M	3.8M	16.9K	1M	1.1M	2.3M	1.9M	2.3M	8.8M	1.3M	626.6K	374K	13.6M
Total Non-Current Liabilities	40M	5.3M	4.4M	4.6M	1.5M	7.2M	4.6M	1.9M	10.5M	442.6K	1M	1.1M	3M	3.6M	2.3M	8.8M	18.7M	1.6M	17M	13.6M
Capital Lease Obligations	1.4M	1.7M	671K	1.1M	1.5M	1.8M	1.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	55M	15.8M	16.5M	21.6M	19.7M	19.2M	8.5M	6.4M	14.4M	205.3M	3.2M	3.7M	9.8M	11.1M	7M	15M	32.2M	37.4M	26M	14.6M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.3M	6K	327.3K	485.8K	0.0	0.0	0.0	0.0	0.0	0.0	66.6M	0.0
Common Stock	11K	7K	7K	5K	4K	3.7K	1.5K	876.0	1.8K	6.8K	6.4K	6.4K	5.2K	4.8K	4.8K	4.6K	2.8K	2.6K	2.2K	1.2K
Additional Paid-In Capital	879.3M	689.9M	665.4M	568.4M	497.3M	417.3M	187.9M	170.2M	121.7M	71M	64M	238.8M	217.9M	210.5M	208.5M	200.8M	157M	142.4M	126.5M	55.8M
Retained Earnings	-649.5M	-561.4M	-466.3M	-377.9M	-293.2M	-186.4M	-137.4M	-116.9M	-77.7M	-29.9M	-223.7M	-220.3M	-210.3M	-198.6M	-193.7M	-189.9M	-156.3M	-123.8M	-87.4M	1.3M
Accumulated Other Comprehensive Income/Loss	-4.9M	-5M	-5M	-5.2M	-5M	-5M	-5M	-5M	-4.6M	-1.1K	-1.9M	-229.5K	-218.7K	-217.3K	1M	1.3M	1.2M	386.4K	1.5M	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.7K	0.0	176.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	71.1M
Total Stockholders' Equity	224.9M	123.5M	194.1M	185.3M	199.1M	225.9M	45.5M	48.3M	48.7M	19.5M	16.6M	18.3M	7.3M	11.7M	15.9M	12.2M	1.9M	19M	40.6M	57.1M
Total Equity	224.9M	123.5M	194.1M	185.3M	199.1M	225.9M	45.5M	48.3M	48.7M	19.5M	16.6M	18.3M	7.3M	11.7M	15.9M	12.2M	1.9M	19M	40.6M	57.1M
SUMMARY
Total Liabilities & Equity	279.9M	139.3M	210.6M	206.9M	218.9M	245.1M	54.1M	54.8M	63M	224.7M	19.9M	22M	17.1M	22.7M	22.8M	27.2M	34.1M	56.4M	66.6M	71.7M
Total Investments	229.7M	95M	62.7M	73.8M	0.0	100M	28.3M	-58.5M	-5.9B	66.8M	0.0	0.0	0.0	0.0	0.0	0.0	3.1M	3.2M	12.2M	0.0
Total Debt	35.7M	1.7M	671K	1.1M	1.5M	1.8M	1.7M	572.8K	49.7K	984.6K	1.1M	746.1K	2.8M	3.8M	0.0	0.0	17.4M	18.3M	20.7M	0.0
Net Debt	-8.1M	-35.2M	-134.4M	-110M	-188.8M	-114.1M	-7.2M	-33.1M	-8.7M	-153M	-14.5M	-17.9M	-7.7M	-8.9M	-11.2M	-11.8M	14.8M	-1.4M	-19.9M	-675.3K
Shares Outstanding	88,257,253	88,257,253	88,257,253	88,257,253	88,257,253	88,257,253	88,257,253	88,257,253	88,257,253	88,257,253	88,257,253	88,257,253	88,257,253	88,257,253	88,257,253	88,257,253	88,257,253	88,257,253	88,257,253	88,257,253

SEC Filings

ALT - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 13, 2026	May 13, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 24, 2026	April 22, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 16, 2026	April 16, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	March 17, 2026	April 16, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 06, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 05, 2026	March 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 03, 2026	February 02, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 28, 2026	January 27, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 19, 2025	December 19, 2025	2025	View Filing

Showing 1 to 10 of 425 filings

Related Guides

Blog Categories

Continue your ALT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.